Iberoamerican Journal of Medicine
https://iberoamjmed.com/article/doi/10.53986/ibjm.2024.0011
Iberoamerican Journal of Medicine
Editorial

Enthesitis and seronegative arthritis induced by Dupilumab: how relevant are these adverse events?

Entesitis y artritis seronegative inducida por Dupilumab: ¿qué tan relevantes son estos eventos adversos?

Angélica María Hurtado Moreno, Urpy Osorio, Jennety Tatiana Peña Forest, Michael Ortega Sierra

Downloads: 2
Views: 645


References

1.Conrad N, Misra S, Verbakel JY, Verbeke G, Molenberghs G, Taylor PN, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet. 2023;401(10391):1878-90. doi: 10.1016/S0140-6736(23)00457-9.
2.Sakamoto E, Katahira Y, Mizoguchi I, Watanabe A, Furusaka Y, Sekine A, et al. Chemical- and Drug-Induced Allergic, Inflammatory, and Autoimmune Diseases Via Haptenation. Biology (Basel). 2023;12(1):123. doi: 10.3390/biology12010123.
3.De Stefano L, Bobbio-Pallavicini F, Montecucco C, Bugatti S. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib. Rheumatology (Oxford). 2022;61(3):e64-e66. doi: 10.1093/rheumatology/keab771.
4.Bridgewood C, Wittmann M, Macleod T, Watad A, Newton D, Bhan K, et al. T Helper 2 IL-4/IL-13 Dual Blockade with Dupilumab Is Linked to Some Emergent T Helper 17‒Type Diseases, Including Seronegative Arthritis and Enthesitis/Enthesopathy, but Not to Humoral Autoimmune Diseases. J Invest Dermatol. 2022;142(10):2660-7. doi: 10.1016/j.jid.2022.03.013.
5.Bridgewood C, Sharif K, Freeston J, Saleem B, Russell T, Watad A, et al. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy. Rheumatology (Oxford). 2021;60(5):2461-6. doi: 10.1093/rheumatology/keaa568.
6.Alroobaea R, Rubaiee S, Hanbazazah AS, Jahrami H, Garbarino S, Damiani G, et al. IL-4/13 Blockade and sleep-related adverse drug reactions in over 37,000 Dupilumab reports from the World Health Organization Individual Case Safety reporting pharmacovigilance database (VigiBase™): a big data and machine learning analysis. Eur Rev Med Pharmacol Sci. 2022;26(11):4074-81. doi: 10.26355/eurrev_202206_28977.
7.Jay R, Rodger J, Zirwas M. Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management. JAAD Case Rep. 2022;21:14-8. doi: 10.1016/j.jdcr.2021.12.011.
8.Lozada-Martinez ID, Suarez-Causado A, Solana-Tinoco JB. Ethnicity, genetic variants, risk factors and cholelithiasis: The need for eco-epidemiological studies and genomic analysis in Latin American surgery. Int J Surg. 2022;99:106589. doi: 10.1016/j.ijsu.2022.106589.
9.Hocking AM, Buckner JH. Genetic basis of defects in immune tolerance underlying the development of autoimmunity. Front Immunol. 2022;13:972121. doi: 10.3389/fimmu.2022.972121.
10.Huang M, Xu H. Genetic susceptibility to autoimmunity-Current status and challenges. Adv Immunol. 2022;156:25-54. doi: 10.1016/bs.ai.2022.08.004.


Submitted date:
01/16/2024

Reviewed date:
03/06/2024

Accepted date:
03/11/2024

Publication date:
03/11/2024

65ef10fda9539533dd2574f4 iberoamericanjm Articles
Links & Downloads

Iberoam J Med

Share this page
Page Sections